Status:
WITHDRAWN
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Lead Sponsor:
Gynecologic Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Fallopian Tube Carcinoma
Hereditary Breast and Ovarian Cancer Syndrome
Eligibility:
FEMALE
30+ years
Brief Summary
This research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the Gynecology Oncology Gr...
Detailed Description
PRIMARY OBJECTIVES: I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of risk-reducing salpingo-oophorectomy (RRSO) versus ovarian cancer screening (OCS) fo...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Women who were eligible and evaluable for GOG-0199, a prospective, non-randomized, natural history study
- Data collected from GOG-0199 available
Exclusion
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01445275
Start Date
January 1 2011
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States, 19103